knowledge -WSS

knowledge

author：comprehensive 2025-09-29 01:09:09 - browse：7

Sorrento Therapeutics — ARIANA DREHSLER/AFP via Getty Images

SAN DIEGO — U.S. legislation that seeks to restrict American biotechs from working with certain Chinese firms and suppliers is for now just that — a proposal, not a law. But the looming bill’s impact was clearly visible at this year’s meeting of the industry’s largest trade group.

A number of biotech companies in attendance at the meeting of the Biotechnology Innovation Organization told STAT they’re actively looking to strike deals with U.S.-based drug manufacturers rather than companies named in the legislation, even though doing so will be more costly. An executive at a U.S.-based contract development and manufacturing organization, or CDMO, who spoke on condition of anonymity, said that “month to month, new business has gone through the roof.”

Meanwhile, some Chinese suppliers not named in the bill are paradoxically drawing increased interest from biotechs — while hearing from some customers worried those manufacturers could be blacklisted in the future.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Change Healthcare can notify patients about the breach, HHS says

Wikipedia

WSS

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

ASCO: Palliative care found as helpful given virtually as in person

BMI, flaws aside, is found to be useful estimate of body fat in youth

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

CVS Caremark has created a new ploy: the drug ‘rebate credit’

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

As demand for Covid shots wanes, Moderna seeks its next success

Colonoscopy prep: Liquid

Wildfire smoke exposes gaps in outdoor worker protections

At ASCO, AstraZeneca reports strong data for breast cancer drug

Guidelines to prevent youth baseball injuries need more muscle

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Asbestos, a deadly carcinogen, banned by EPA

The cancer drug shortage isn’t new — and neither are the solutions

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

hotspot

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Readout Newsletter: Bluebird, CVS, Contineum

ASCO: AstraZeneca says CAR

Neuroscience’s long legacy of racism

Innovation in antibiotics is ailing. 'Brain drain' may kill it

ASCO: AstraZeneca says CAR

Wikipedia

focus

knowledge

knowledge